A randomized, double-blind, placebo-controlled, parallel group, phase 4, multi-center study of Vesicare (solifenacin succinate) in overactive bladder (OAB) subjects to evaluate symptom bother and health related quality of life VIBRANT: VESIcare Investigation of Bother And Quality of Life in Subjects with OAB
Latest Information Update: 20 Aug 2023
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms VIBRANT
- Sponsors Astellas Pharma
- 01 Jan 2010 Secondary endpoint 'Quality of life instrument' (change in HRQL total and domain scores on the OAB-q) has been met.
- 16 May 2009 Results have been presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 06 May 2009 Primary endpoint 'Overactive Bladder Questionnaire' (change from baseline in OAB-q symptom bother scale score at 12 weeks) has been met.